SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Merit Medical Systems, Inc. (MMSI) trades at a trailing P/E of 31.4, forward P/E of 17.5. Trailing earnings yield is 3.18%, forward earnings yield 5.73%. PEG 6.41. Graham Number is $36.06.
Criteria proven by this page:
- VALUE (40/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 17.5 (down from trailing 31.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 6.41 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 3.18% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.73% as earnings recover.
- Analyst consensus target $100.67 (+42.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 70/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
40/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MMSI
Valuation Multiples
P/E (TTM)31.4
Forward P/E17.5
PEG Ratio6.41
Forward PEG0.19
P/B Ratio2.55
P/S Ratio2.67
EV/EBITDA13.5
Per Share Data
EPS (TTM)$2.17
Forward EPS (Est.)$4.04
Book Value / Share$26.70
Revenue / Share$25.54
FCF / Share$4.25
Yields & Fair Value
Earnings Yield3.18%
Forward Earnings Yield5.73%
Dividend Yield0.00%
Graham Number$36.06
SharesGrow IV$127.25 (+80.4%)
Analyst Target$100.67 (+42.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
58.5 |
-3.51 |
2.36 |
1.95 |
- |
| 2017 |
76.6 |
3.13 |
3.12 |
2.90 |
- |
| 2018 |
69.4 |
1.62 |
3.13 |
3.30 |
- |
| 2019 |
315.4 |
-3.60 |
1.81 |
1.73 |
- |
| 2020 |
-312.6 |
1.11 |
3.21 |
3.19 |
- |
| 2021 |
72.2 |
-0.12 |
3.36 |
3.25 |
- |
| 2022 |
53.8 |
1.03 |
3.51 |
3.49 |
- |
| 2023 |
46.3 |
1.84 |
3.64 |
3.48 |
- |
| 2024 |
46.8 |
1.78 |
4.08 |
4.15 |
- |
| 2025 |
40.6 |
8.40 |
3.29 |
3.44 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.45 |
$603.84M |
$20.12M |
3.3% |
| 2017 |
$0.55 |
$727.85M |
$27.52M |
3.8% |
| 2018 |
$0.78 |
$882.75M |
$42.02M |
4.8% |
| 2019 |
$0.10 |
$994.85M |
$5.45M |
0.5% |
| 2020 |
$-0.18 |
$963.88M |
$-9.84M |
-1% |
| 2021 |
$0.84 |
$1.07B |
$48.45M |
4.5% |
| 2022 |
$1.29 |
$1.15B |
$74.52M |
6.5% |
| 2023 |
$1.62 |
$1.26B |
$94.41M |
7.5% |
| 2024 |
$2.03 |
$1.36B |
$120.36M |
8.9% |
| 2025 |
$2.13 |
$1.52B |
$128.49M |
8.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$4.06 |
$4.02 – $4.07 |
$1.62B |
$1.61B – $1.63B |
7 |
| 2027 |
$4.39 |
$4.32 – $4.52 |
$1.71B |
$1.69B – $1.73B |
7 |
| 2028 |
$4.65 |
$4.33 – $4.96 |
$1.8B |
$1.79B – $1.81B |
2 |
| 2029 |
$4.97 |
$4.91 – $5.04 |
$1.92B |
$1.91B – $1.95B |
1 |
| 2030 |
$5.23 |
$5.16 – $5.31 |
$2.06B |
$2.04B – $2.08B |
1 |
